Despite recent successes in the treatment of solid tumors using highly promising immunotherapeutic agents, the prognosis for most cancer patients remains dire. Only a small subset of patients responds well to PD(L)-1 immune checkpoint inhibitors, while the majority either fail to respond, experience rapid tumor recurrence after initial treatment success, or are overcome by severe toxicities that restrict further treatment options. The limited success rate of immunotherapy is directly linked to the high heterogeneity found in both the preexisting immune response variability and the clonality of the tumor. To overcome these issues, it is critical to find robust, sensitive, and specific predictive and prognostic biomarkers for immunotherapy. Advanced proteomics technologies are enabling an easy, rapid, and noninvasive means for discovering blood-based biomarkers that promise to identify tumor and immune changes associated with immune checkpoint inhibitor response/nonresponse, and uncover biological insights underlying primary resistance and toxicity. At the same time, analysis of liquid biopsies of blood or other bodily fluids have recently showed promise in predicting response to anti-PD(L)-1 therapy. It is also clear that multiprotein signatures may be more powerful and reliable than single protein markers, while combining protein biomarkers with other 'omics approaches and sophisticated data analysis techniques holds enormous potential to establish predictive and/or monitoring tools for immunotherapy.
During the webinar, the speakers will:
- Explain how whole-plasma proteomic profiling in melanoma and non–small cell lung cancer (NSCLC) patients enables discovery of blood-based biomarkers to predict immunotherapy responses, including resistance and toxicity
- Describe how changes in immune activation during immunotherapy and radiation could be tracked by differentially expressed plasma proteins
- Clarify how proteomic and transcriptomic biomarkers along with tumor-based analyses can drive patient selection and provide clinically actionable information
- Demonstrate the relationship of plasma biomarkers to overall survival and progression-free survival in patients with advanced melanoma undergoing immunotherapy
- Answer viewer questions during the live broadcast.
This webinar will last for approximately 60 minutes.